Since evidence suggests that β-TrCP1/2 are potential targets to treat certain types of cancers, further studies on the transcriptional and post-translational modulation on β-TrCP1/2 warrant the development of new therapeutic entities to overcome malignant diseases. Here, BTRC is linked to cancer.